Solutions - Page 2

Amid a nearly $1 billion GLP-1 manufacturing expansion that began in 2024, CMDO CordenPharma is doubling down on its peptide capacity ambitions.

Korea’s SK bioscience has signed a technology transfer and manufacturing deal with the Colombian government which will allow the South American nation to produce the company’s chickenpox vaccine SKYVaricella.

Niowave has broken ground on a $75 million facility at its campus in Lansing, Michigan, which will produce Actinium-225. The radioisotope supplier expects the facility to become operational in 2028 and to

Gilead has broadened its partnership with Korean manufacturer Yuhan, agreeing to a $140 million supply deal for active pharmaceutical ingredients for an undisclosed product.

A Novartis cross-border partnership is turning into a standoff. The Swiss pharma has unilaterally terminated a plant leasing contract with Chinese CDMO Porton Pharma Solutions after a regulatory hiccup.

As Bristol Myers looks for suitable sites for a large U.S. manufacturing plant, Houston has emerged as one contender.

As biologics have increasingly superseded small molecules in the biopharma industry’s pipeline, the mounting complexity of their manufacturing products is putting production and launches under pressure.

Generics juggernaut Sun Pharma is pulling one lot of a chemotherapy drug in the United States as the issue of particulate contamination crops up once again on the FDA’s recall register.

Taiwan’s Bora Group will shell out up to $127.5 million to acquire the CDMO business and manufacturing operations from Maryland-based MacroGenics.

After positive momentum on the plan in late 2025, European Union lawmakers have taken a critical step toward implementing a new framework for the bloc focused on boosting supplies of critical medicines